Loading…
Chinese maker of insulin and insulin analogs, competing with multinational diabetes-drug makers domestically and via partners abroad.
Chinese maker of insulin and insulin analogs, competing with multinational diabetes-drug makers domestically and via partners abroad.
Sells insulin to Chinese hospitals mainly through government volume-based tenders, which trade lower prices for guaranteed volumes. Outside China it licenses products to partners, including Sandoz, that run approvals and sales in their markets. Newer candidates in the GLP-1 class, used for diabetes and weight loss, are in development.
In one line: China's Novo Nordisk for insulin.
Moat: narrow (scale, process know-how, regulatory licence). One of few Chinese makers with FDA-relevant insulin manufacturing and international partnerships.
Headquarters: Beijing, China · Founded: 1998 · Employees: 5,309
Size Gan & Lee Pharmaceuticals (603087.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $6.40B, the 390th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥71.38 on 6 Nov 2026.
Performance Over six months the shares gained 21.3%, against -0.5% for the median peer and -16.4% for the China market (cap-weighted) — 7th highest of 20 in its peer set.
Growth Revenue grew 14.2% over the last twelve months (peer median +6.0%); the operating margin is 20.3% (peer median 16.5%).
Valuation It trades at 29.7× forward earnings against a peer median of 24.0× (6th most expensive of 16).
Capital Return on invested capital runs 2.6 points above its cost of capital (8.3% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥4.37B | CN¥4.04B | CN¥3.01B | CN¥2.60B | CN¥1.71B |
| Revenue growth | — | +34% | +16% | +52% | — |
| Gross profit | CN¥3.45B | CN¥2.94B | CN¥2.13B | CN¥1.80B | CN¥1.20B |
| EBITDA | n/a | CN¥1.07B | CN¥555M | CN¥407M | -CN¥474M |
| Net income | CN¥1.18B | CN¥1.14B | CN¥615M | CN¥340M | -CN¥440M |
| Free cash flow | -CN¥159M | -CN¥49.2M | CN¥185M | -CN¥125M | -CN¥505M |
| Capital expenditure | CN¥1.33B | CN¥926M | CN¥441M | CN¥553M | CN¥983M |
| Total debt | CN¥235M | CN¥121M | CN¥200M | CN¥79.0M | CN¥85.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Gan & Lee Pharmaceuticals 603087.SS | $6.40B | +21% | +14% | 20% | 29.7× | n/a |
| Novo Nordisk A/S NOVO-B.CO | $190B | -7% | +6% | 48% | 11.9× | 0.1% |
| Lilly (Eli) LLY | $1.27T | +43% | +46% | 51% | 28.9× | 5.9% |
| Tonghua Dongbao Pharmaceutical 600867.SS | $2.29B | -14% | +18% | n/a | 26.2× | 1.6% |
| Sanofi SAN.PA | $113B | +14% | +15% | 27% | 9.6× | -5.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603087.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.0% | +2.4% | 4th lowest of 21 |
| 6-month return | +21.3% | -0.5% | 7th highest of 20 |
| Distance from 52-week high | -10.8% | -14.1% | 8th highest of 21 |
| Revenue growth (TTM) | +14.2% | +6.0% | 6th highest of 17 |
| Operating margin | 20.3% | 16.5% | 6th highest of 18 |
| Forward P/E | 29.7× | 24.0× | 6th most expensive of 16 |
| ROIC minus cost of capital | +2.6 pp | +1.5 pp | 9th highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Gan & Lee Pharmaceuticals 603087.SS | China | $6.40B | +21% | +14% | 20% | 29.7× | n/a | n/a |
| Samsung Epis 0126Z0.KS | South Korea | $6.39B | -36% | n/a | -25% | 24.0× | n/a | n/a |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | China | $6.48B | 0% | +4% | 14% | 12.8× | -6.3% | +18.4% |
| Biocon BIOCON.NS | India | $6.28B | -4% | +6% | 8% | 56.4× | n/a | n/a |
| Ionis Pharmaceuticals IONS | United States | $6.55B | -48% | -7% | -68% | n/a | n/a | n/a |
| Belite Bio, Inc. ADR BLTE | United States | $6.20B | 0% | n/a | n/a | n/a | n/a | n/a |
| Alkem Laboratories ALKEM.NS | India | $6.67B | -5% | +13% | 17% | 27.4× | 24.3% | +10.7% |
| Ligand Pharmaceuticals LGND | United States | $6.12B | +38% | +1% | 14% | 28.0× | 57.8% | +7.5% |
| Mirum Pharmaceuticals MIRM | United States | $6.12B | -13% | +42% | -21% | n/a | n/a | n/a |
| Oruka Therapeutics ORKA | United States | $6.81B | +59% | n/a | n/a | n/a | n/a | n/a |
| Abbott India ABBOTINDIA.NS | India | $5.93B | -1% | +6% | 28% | 32.4× | 11.4% | +10.0% |
| RemeGen 688331.SS | China | $6.90B | -26% | +272% | 61% | 11.9× | 2.8% | +303.3% |
| Shanghai Allist Pharmaceuticals 688578.SS | China | $5.90B | -6% | +39% | 47% | 13.8× | 1.8% | +519.6% |
| ONO Pharmaceutical 4528.T | Japan | $7.01B | +2% | -2% | 22% | 14.7× | -8.2% | +10.8% |
| Amneal Pharmaceuticals AMRX | United States | $7.01B | +53% | +9% | 17% | 17.7× | 15.2% | +8.7% |
| Veradermics MANE | United States | $5.80B | +31% | n/a | n/a | n/a | n/a | n/a |
| Apotex Health APTX.TO | Canada | $5.62B | n/a | +4% | 32% | 18.6× | -13.5% | +4.2% |
| Huadong Medicine 000963.SZ | China | $7.29B | -17% | +2% | 9% | 14.0× | -2.7% | +5.3% |
| Bachem BANB.SW | Switzerland | $7.32B | +3% | +5% | 19% | 33.1× | n/a | n/a |
| Kiniksa Pharmaceuticals International KNSA | United States | $7.37B | +60% | +58% | 14% | 61.7× | 9.9% | +45.5% |
| Gland Pharma GLAND.NS | India | $5.53B | +69% | +18% | 20% | 39.0× | 28.0% | +13.3% |